Teva sells as many as 4 assets: Medis, respiratory, women’s health and oncology

Teva Pharmaceuticals Industries is weighing a sale of Medis, an Icelandic unit that develops generics for other companies, and of its respiratory treatment assets, people familiar with the matter said. According to analysts, divesting Medis is likely to fetch Teva $500m to $1bn, while the respiratory business is valued $500m to $2bn. The divestiture reportedly addresses the need to reduce debt, which exceeds $35bn, and to offset the negative quarter, with Teva losing $6bn. The company is also receiving offers for its women’s health unit and and its European oncology and pain treatments. The latter drew interest from drugmakers such as Fresenius SE, Mylan NV, Novartis AG; the former attracted private equity firms, the people said.
(Source: Bloomberg)